摘要：
目的 观察脉络膜血管造影(ICGA)引导的光动力疗法(PDT)治疗孤立性脉络膜血管瘤(CCH)的临床疗效.方法 采用回顾性系列病例观察方法,对2010年8月至2018年5月在徐州市立医院确诊并行PDT治疗的CCH患者17例17眼的临床资料进行分析,患眼均行光相干断层扫描(OCT)、荧光素眼底血管造影(FFA)联合同步ICGA以及彩色多普勒超声显像(CDI)检查,根据ICGA图像确定病灶范围后进行PDT治疗.随访6～36个月,平均(23.3±1 1.8)个月,比较患眼PDT治疗前后最佳矫正视力(BCVA),采用OCT评估患眼治疗前后视网膜下积液(SRF)和黄斑中心视网膜厚度(CRT)变化,采用ICGA观察瘤体直径,采用CDI测量瘤体厚度.结果 16例患者行单次PDT治疗,1例有PDT治疗史,1例有眼底激光光凝治疗史.治疗前和治疗后1周、1个月、3个月、末次随访患眼BCVA(LogMAR视力)分别为0.99±0.52、1.09±0.50、0.97±0.53、0.81±0.66和0.79±0.69,CRT分别为(440.76±281.34)、(329.18±175.02)、(274.24± 169.55)、(271.53±150.00)和(291.06±201.41) μm,总体比较差异均有统计学意义(F=6.965,P=0.006;F=8.784,P=0.002).与治疗前比较,末次随访标准对数视力提高2行及以上者9例,占52.9％;视力浮动在2行以内者7例,占41.2％;视力下降2行及以上者1例,占5.9％.息眼治疗前OCT示SRF均累及黄斑区;治疗后3个月,7眼SRF完全吸收,占41.2％,8眼SRF明显减少,占47.1％;末次随访,12眼SRF完全吸收,占70.6％,3眼SRF明显减少,占17.6％,2眼SRF未吸收,占11.8％.与治疗前比较,治疗后各随访时间点CRT值均下降,差异均有统计学意义(均P＜0.05).所有患眼治疗前FFA及ICGA早期均显示类圆形强荧光,ICGA强荧光的范围大于FFA;末次随访瘤体最大直径较治疗前缩小者15眼,占88.2％.治疗前和末次随访瘤体厚度分别为(3.80±1.13)mm和(3.42±1.14)mm,差异有统计学意义(t=4.101,P=0.010). 结论 ICGA引导下的PDT治疗CCH可改善患眼视功能,促进SRF吸收,致瘤体萎缩.大多数患者经单次PDT治疗就能达到较好的治疗效果.%Objective To observe the efficacy of photodynamic therapy (PDT) based on indocyanine green angiography (ICGA) for circumscribed choroidal hemangioma (CCH).Methods A retrospective observational case series study was performed.Seventeen eyes of 17 patients were diagnosed with CCH and then underwent PDT based on ICGA image in Xuzhou Municipal Hospital from August,2010 to May,2018.The size of the treatment spot was decided according to ICGA images.The period of mean follow-up visit ranged from 6 to 36 months,with an average of (23.3± 1 1.8) months.Best corrected visual acuity (BCVA),sub-retinal fluid (SRF) and central retinal thickness (CRT) based on optical coherence tomography (OCT),the tumor diameter based on ICGA and the tumor thickness based on coloured doppler imaging (CDI) before and after treatment were analyzed.Results Sixteen cases received only one PDT session,one case had ever received PDT and another case had ever received focal laser photocoagulation.The mean BCVA (LogMAR) was 0.99±0.52,1.09±0.50,0.97±0.53,0.81±0.66,0.79±0.69,and the mean CRT was (440.76±281.34),(329.18± 175.02),(274.24± 169.55),(271.53 ± 150.00),(291.06 ± 201.41)μm before PDT,at 1 week,1 month,3 months and the last visit after treatment,with significant differences among the follow-up time (F =6.965,P =0.006;F =8.784,P =0.002).The decimal visual acuity was increased by at least 2 lines in 9 eyes (52.9％),fluctuated within 2 lines in 7 eyes (41.2％),while decreased by at least 2 lines in one eye (5.9％).SRF of all patients was involved in macular area.The absolute absorption of SRF was found in 7 eyes (41.2％) and partial absorption in 8 eyes (47.1％) at 3 months follow-up visit.In the last follow-up visit,the absolute absorption of SRF was found in 12 eyes (70.6％),partial absorption was found in 3 eyes (17.6％) and 2 eyes (11.8％) underwent no change.On FFA and ICGA,the decrease of tumor size was found in 15 patients,while the others underwent no change.All patients underwent less enhanced hyperfluorescent after treatment.The mean tumor height was (3.80± 1.13)mm before PDT and (3.42± 1.14)mm on the last visit,with a significant difference between them (t=4.101,P=0.010).Conclusions PDT with verteporfin for CCH can promote the improvement of visual acuity,the absorption of SRF,the anatomical reposition of the retina and the decrease of tumor size.The majority of patients can get therapeutic effect after one PDT session.
